

BlueStar Investment Managers



Our key team

BlueStar Investment Managers SA Investment Manager of Onelife Fund



- * Massimo Colnago
- * Fund Manager

Massimo Colnago, M.Sc. (Economics), ONELIFE FUND Manager has over 20 years experience in capital markets, portfolio analysis, wealth management and trading in Switzerland and UK.

External Advisors and Sector Specialists



- * Enrico Braglia
- * ONELIFE Founder and Onelife Fund Initiator

Enrico Braglia, M.Sc. (Economics), ONELIFE founder has over 25 years experience in healthcare in top executive positions and boards. He is involved in a number of professional and no profit international organizations, founder and board member in several innovative companies.



- * Federica Pericle
- * Scientific and Strategic Advisor

Federica Pericle, PhD, MBA, Scientific and Strategic Advisor has over 25 years experience in research and development in public institutions, universities and in top executive position and boards in US companies

What is life science?

- * Healthcare: The act of taking preventative or necessary medical procedures to improve a person's well-being.
- * Pharmaceutical: The industry discovers, develops, produces, and markets drugs for use as medications.
- * Biotechnology: the manipulation of living organisms or their components to produce commercial products.
- * Life Sciences: include companies in the fields of biopharmaceuticals, pharmaceuticals, biomedical technologies, nutraceuticals, cosmeceuticals, environmental, ...

```
graph TD; A[Healthcare] --> B[Healthcare Equipment & Services]; A --> C[Pharmaceuticals & Biopharmaceuticals]
```

Healthcare


Healthcare
Equipment & Services

Pharmaceuticals &
Biopharmaceuticals

Healthcare overperformed the S&P 500 over 10 years

The Facts:



- * Great earnings potential (most rewarding sector)
- * Life Science market growth +8%(y/y)
- * M&A and news-flow drive the market
- * The world's population is living longer
- * 50% of all diseases have NO cure
- * Constant need for new drugs




The complexity of the life science sector

- * Over \$1.5bn are the costs of a new drug
- * 12 years is the average time to develop a new drug
- * Ca.10% is the probability of success for a drug entering the clinic
- * On average there are only 32 new approved products per year.


FDA Approvals 2000-2019



Lowering the risk: global, diversified and late stage



ONELIFE model in life science



- * Hands-on experience in every stage of the development and the commercial rollout
- * Unique combination of industry expertise and financial know-how
- * Direct presence in USA

(* The database is sorted by company size, group (i.e. R&D), country, therapeutic area

2020 and beyond...

THREATS

- * High volatility and sentiment will continue
- * US mid-term presidential election
- * US pressure on pricing
- * Patent expiration and biosimilars
- * "Trade wars" influencing this sector too

OPPORTUNITIES

- * Over 350 events in 2020
- * New innovation (i.e. NASH, Gene Therapy)
- * Possibly >50 approvals of new drugs
- * Company valuations are still attractive
- * M&A and news-flow drive the market

Onelife Fund Details

GENERAL INFORMATION

Management Company	VP Fund Solutions AG	
Investment Manager	BlueStar Investment Managers SA	
NAV Frequency	Daily	
Minimum Investment	1'000 USD	
Launch Date	08/05/2015	
Domicile	Liechtenstein	
Custodian Bank	VP Bank AG, Vaduz	
Legal Status	UIT, UCITS V	
Country of registration	LI, CH*	(* Qualified investors only)

LAUNCHED CLASSES

ISIN	BLOOMBERG	CCY	CLASS	MANAGEMENT FEES
LI0269512732	ONELIFU LE Equity	USD		1.18%
LI0465136930	ONELFUB LE Equity	USD	B	1.68%


Why Onelife Fund?

- * Focus only in the Pharmaceutical and Biopharmaceutical Sector
- * Unique combination of Industry Expertise and Financial know-how
- * >70 years of combined experience
- * Direct presence in USA
- * Team is privately invested in the fund
- * 15 years of track record

Contact

BlueStar Investment Managers SA
Via G. B. Pioda 8
CH – 6900 Lugano

T: +41 91 260 36 70
F: +41 91 260 36 71
E: info@bluestarim.ch
www.bluestarim.ch



Disclaimer

This document is for information purposes and it represents advertisement material and it is based on the prospectus and on the key information document of the fund ONELIFE FUND which are available upon request by BlueStar Investment Managers SA (registered office in Lugano, Via G.B. Pioda 8, E-mail address: info@bluestar-im.ch, Telephone number: +41 91 260 36 70). The present set of information are available only to investors resident in Switzerland, Italy and Luxembourg. The performances figures shown in this document are based on either estimated or final prices as supplied to BlueStar by third party information providers. Although BlueStar and its information providers seek to ensure that such information is accurate and has been obtained from sources presumed to be reliable, no warranty, expressed or implied, is made as to its accuracy and BlueStar shall not be held liable for any inaccuracies or incompleteness. Past performance is not necessarily indicative of future results. This document is strictly confidential. It is made with the aim of informing BlueStar's clients and may not be redistributed to third parties albeit related to BlueStar's client without the express, written consent of BlueStar. The information contained in this document shall not be considered as legal, tax, regulatory or other advice. Its recipient should obtain relevant and specific advice regarding its local regulation before making any investment decision.